(CCJ) Cameco - Ratings and Ratios

Exchange: NYSE • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA13321L1085

Uranium, Fuel Services, Reactor Technology, Components, Spare Parts

Dividends

Dividend Yield 0.19%
Yield on Cost 5y 1.43%
Yield CAGR 5y 16.92%
Payout Consistency 90.8%
Payout Ratio 13.1%
Risk via 10d forecast
Volatility 49.9%
Value at Risk 5%th 78.1%
Relative Tail Risk -4.82%
Reward TTM
Sharpe Ratio 0.98
Alpha 36.86
CAGR/Max DD 1.56
Character TTM
Hurst Exponent 0.377
Beta 1.205
Beta Downside 1.096
Drawdowns 3y
Max DD 40.01%
Mean DD 9.55%
Median DD 6.33%

Description: CCJ Cameco December 03, 2025

Cameco Corp (NYSE:CCJ) is a vertically integrated uranium producer headquartered in Saskatoon, Canada. It operates three distinct segments: Uranium (exploration, mining, milling, and sales of U₃O₈ concentrate), Fuel Services (conversion, enrichment, and fabrication of nuclear fuel), and Westinghouse (design, OEM, and aftermarket services for commercial nuclear reactors). Its customer base spans nuclear utilities across the Americas, Europe, and Asia.

As of 2023, Cameco generated roughly 7.2 million lb of U₃O₈, with an average cash cost of about $30 per lb, positioning it among the lowest-cost producers globally. The company’s net debt stood at ≈ $1.5 billion, yielding a net-debt/EBITDA ratio of ~ 1.2×, which suggests moderate leverage relative to peers. Spot uranium prices have hovered near $55 / lb (2024-Q1), while long-term contract prices remain in the $65-$70 / lb band, creating a price-spread tailwind for cash flow.

The uranium market is currently driven by three macro forces: (1) a tightening supply outlook as legacy mines curtail output, (2) policy-driven nuclear expansion-particularly in China, India, and the United States-targeting an estimated + 30 GW of new capacity by 2035, and (3) heightened geopolitical risk that favours domestic supply chains for strategic materials. Assuming uranium demand grows at the sector-wide consensus rate of 2-3 % annually, Cameco’s low-cost profile could translate into a 10-15 % upside in earnings under a modest price recovery scenario; however, this projection is highly sensitive to spot-price volatility and the pace of new reactor construction.

For a deeper, data-driven look at Cameco’s valuation scenarios and sensitivity analyses, the ValueRay platform provides a transparent, up-to-date toolkit worth exploring.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (526.0m TTM) > 0 and > 6% of Revenue (6% = 207.9m TTM)
FCFTA 0.10 (>2.0%) and ΔFCFTA 6.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 36.28% (prev 35.41%; Δ 0.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 1.26b > Net Income 526.0m (YES >=105%, WARN >=100%)
Net Debt (228.5m) to EBITDA (1.07b) ratio: 0.21 <= 3.0 (WARN <= 3.5)
Current Ratio 2.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (435.4m) change vs 12m ago -0.02% (target <= -2.0% for YES)
Gross Margin 29.05% (prev 23.81%; Δ 5.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 36.41% (prev 30.11%; Δ 6.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 9.32 (EBITDA TTM 1.07b / Interest Expense TTM 79.9m) >= 6 (WARN >= 3)

Altman Z'' 4.87

(A) 0.13 = (Total Current Assets 1.89b - Total Current Liabilities 631.4m) / Total Assets 9.74b
(B) 0.36 = Retained Earnings (Balance) 3.49b / Total Assets 9.74b
(C) 0.08 = EBIT TTM 744.0m / Avg Total Assets 9.51b
(D) 2.22 = Book Value of Equity 6.57b / Total Liabilities 2.96b
Total Rating: 4.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 72.42

1. Piotroski 8.0pt
2. FCF Yield 1.81%
3. FCF Margin 28.07%
4. Debt/Equity 0.15
5. Debt/Ebitda 0.21
6. ROIC - WACC (= -1.32)%
7. RoE 7.98%
8. Rev. Trend 73.46%
9. EPS Trend 40.47%

What is the price of CCJ shares?

As of December 06, 2025, the stock is trading at USD 91.27 with a total of 3,231,660 shares traded.
Over the past week, the price has changed by +3.32%, over one month by -3.98%, over three months by +20.56% and over the past year by +49.57%.

Is CCJ a buy, sell or hold?

Cameco has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy CCJ.
  • Strong Buy: 10
  • Buy: 9
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CCJ price?

Issuer Target Up/Down from current
Wallstreet Target Price 113.7 24.6%
Analysts Target Price 113.7 24.6%
ValueRay Target Price 142.1 55.7%

CCJ Fundamental Data Overview November 29, 2025

Market Cap CAD = 53.39b (38.65b USD * 1.3815 USD.CAD)
P/E Trailing = 102.9186
P/E Forward = 66.2252
P/S = 11.1565
P/B = 8.0471
P/EG = 3.33
Beta = 1.311
Revenue TTM = 3.46b CAD
EBIT TTM = 744.0m CAD
EBITDA TTM = 1.07b CAD
Long Term Debt = 996.2m CAD (from longTermDebt, last quarter)
Short Term Debt = 289.2m CAD (from shortTermDebt, last fiscal year)
Debt = 1.01b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 228.5m CAD (from netDebt column, last quarter)
Enterprise Value = 53.62b CAD (53.39b + Debt 1.01b - CCE 778.7m)
Interest Coverage Ratio = 9.32 (Ebit TTM 744.0m / Interest Expense TTM 79.9m)
FCF Yield = 1.81% (FCF TTM 972.5m / Enterprise Value 53.62b)
FCF Margin = 28.07% (FCF TTM 972.5m / Revenue TTM 3.46b)
Net Margin = 15.18% (Net Income TTM 526.0m / Revenue TTM 3.46b)
Gross Margin = 29.05% ((Revenue TTM 3.46b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 37.32% (prev 29.31%)
Tobins Q-Ratio = 5.51 (Enterprise Value 53.62b / Total Assets 9.74b)
Interest Expense / Debt = 0.60% (Interest Expense 6.05m / Debt 1.01b)
Taxrate = 101.0% (out of range, set to none) (15.9m / 15.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.99 (Total Current Assets 1.89b / Total Current Liabilities 631.4m)
Debt / Equity = 0.15 (Debt 1.01b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 0.21 (Net Debt 228.5m / EBITDA 1.07b)
Debt / FCF = 0.23 (Net Debt 228.5m / FCF TTM 972.5m)
Total Stockholder Equity = 6.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.40% (Net Income 526.0m / Total Assets 9.74b)
RoE = 7.98% (Net Income TTM 526.0m / Total Stockholder Equity 6.59b)
RoCE = 9.80% (EBIT 744.0m / Capital Employed (Equity 6.59b + L.T.Debt 996.2m))
RoIC = 8.93% (EBIT 744.0m / (Assets 9.74b - Curr.Liab 631.4m - Cash 778.7m))
WACC = 10.26% (E(53.39b)/V(54.40b) * Re(10.45%) + (debt cost/tax rate unavailable))
Discount Rate = 10.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
[DCF Debug] Terminal Value 74.02% ; FCFE base≈700.8m ; Y1≈864.6m ; Y5≈1.48b
Fair Price DCF = 38.50 (DCF Value 16.76b / Shares Outstanding 435.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 40.47 | EPS CAGR: 4.20% | SUE: -0.93 | # QB: 0
Revenue Correlation: 73.46 | Revenue CAGR: 7.75% | SUE: -0.58 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.38 | Chg30d=-0.096 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=1.97 | Chg30d=-0.129 | Revisions Net=-5 | Growth EPS=+42.4% | Growth Revenue=+7.1%

Additional Sources for CCJ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle